Solventum (SOLV) Stock Price, News & Analysis

Company Overview

Solventum (NYSE:SOLV) is a global specialty chemicals company primarily engaged in the production and distribution of high-performance solvents, surfactants, and related chemical intermediates. The company’s product portfolio serves a wide range of industries, including coatings and inks, personal care and cosmetics, pharmaceuticals, agrochemicals, and industrial cleaning. Solventum emphasizes customized formulations to meet specific customer requirements, addressing both performance and regulatory demands.

In addition to standard product lines, Solventum offers contract manufacturing, technical support, and laboratory services to accelerate product development and scale-up. The company operates multiple research and development centers where its teams collaborate with clients on sustainable chemistry initiatives, focusing on low-VOC (volatile organic compound) formulations, bio-based solvents, and waste-reduction processes. This commitment to innovation has positioned Solventum as a partner of choice for companies seeking environmentally responsible solutions.

Founded in 1995, Solventum has grown through organic expansion and strategic acquisitions. The company’s headquarters is located in Houston, Texas, and it maintains major production facilities in the United States, Europe, and Asia. Over the past two decades, Solventum has invested in capacity enhancements and technology upgrades to support rising demand in emerging markets, particularly in China, India, and Latin America.

Leadership at Solventum is led by Chief Executive Officer John A. Thompson, who has steered the company toward sustainable growth strategies since his appointment in 2018. Chief Financial Officer Jane L. Roberts oversees financial planning and risk management, while Chief Technology Officer Dr. Emily Chen directs research and innovation efforts. Together, the management team continues to expand Solventum’s global footprint, focusing on operational excellence and customer-centric solutions.

Key Stats

• Today's Range: $74.83 to $76.71
• 50-Day Range: $65.57 to $78.21
• 52-Week Range: $47.16 to $85.92
• Volume: 1.03 million shs
• Average Volume: 1.12 million shs
• Market Capitalization: $12.98 billion
• P/E Ratio: 34.75
• Dividend Yield: N/A
• Price Target: $81.50
• Consensus Rating: Hold

Solventum Stock Analysis - MarketRank™

Solventum scored higher than 16% of companies evaluated by MarketBeat, and ranked 862nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Solventum has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Solventum has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -16.57%

Earnings Growth

Earnings for Solventum are expected to decrease by -16.57% in the coming year, from $6.58 to $5.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Solventum is 34.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Solventum is 34.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.05.

Price to Earnings Growth Ratio

Solventum has a PEG Ratio of 2.01. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Solventum has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.03% of the float of Solventum has been sold short.

Short Interest Ratio / Days to Cover

Solventum has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Solventum has recently decreased by 6.67%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solventum does not currently pay a dividend.

Dividend Growth

Solventum does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.03% of the float of Solventum has been sold short.

Short Interest Ratio / Days to Cover

Solventum has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Solventum has recently decreased by 6.67%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.98

News Sentiment

Solventum has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Solventum this week, compared to 12 articles on an average week.

Search Interest

4 people have searched for SOLV on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Solventum to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Solventum insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.05% of the stock of Solventum is held by insiders.

SOLV Stock Analysis - Frequently Asked Questions

How have SOLV shares performed this year?

Solventum's stock was trading at $66.06 at the start of the year. Since then, SOLV stock has increased by 13.6% and is now trading at $75.05.

How were Solventum's earnings last quarter?

Solventum Corporation (NYSE:SOLV) announced its quarterly earnings results on Thursday, May, 8th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.19 by $0.15. The firm's quarterly revenue was up 2.7% compared to the same quarter last year.
Read the conference call transcript.

Who are Solventum's major shareholders?

Top institutional shareholders of Solventum include Parallel Advisors LLC and Ransom Advisory Ltd.

How do I buy shares of Solventum?

Shares of SOLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Solventum own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Solventum investors own include Chevron (CVX), American Water Works (AWK), The RMR Group (RMR), Bristol Myers Squibb (BMY), DiamondRock Hospitality (DRH), Waste Connections (WCN) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:SOLV
• Previous Symbol: NYSE:SOLV
• CIK: 1964738
• Web: www.solventum.com
• Phone: 651-733-1110
• Fax: N/A
• Employees: 22,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Solventum: $81.50
• High Price Target: $90.00
• Low Price Target: $71.00
• Potential Upside/Downside: +8.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.18
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.16
• Trailing P/E Ratio: 34.75
• Forward P/E Ratio: 11.41
• P/E Growth: 2.01
• Net Income: $478 million
• Net Margins: 4.55%
• Pretax Margin: 3.78%
• Return on Equity: 31.01%
• Return on Assets: 6.53%

Debt

• Debt-to-Equity Ratio: 2.40
• Current Ratio: 1.19
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $8.25 billion
• Price / Sales: 1.57
• Cash Flow: $9.50 per share
• Price / Cash Flow: 7.90
• Book Value: $17.13 per share
• Price / Book: 4.38

Miscellaneous

• Outstanding Shares: 173,010,000
• Free Float: 172,926,000
• Market Cap: $12.98 billion
• Optionable: Optionable
• Beta: 0.55